Inhibitory effects of IL-6 on IGF-1 activity in skeletal myoblasts could be mediated by the activation of SOCS-3

Journal of Cellular Biochemistry

Volumn 113, Issue 3, 2012, Pages 923-933

  Al Shanti, Nasser ^a   Stewart, Claire E ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Cyclin D1; Differentiation; Igf 1; Il 6; Myoblasts

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYOGENIC FACTOR; PROTEIN KINASE B; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CHEMICAL ANALYSIS; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL DEATH; CELL LINE; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MICE; MYOBLASTS, SKELETAL; MYOGENIC REGULATORY FACTORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MURINAE;

EID: 84857590655     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23420     Document Type: Article

References (67)

1. Adams GR, Vaziri ND. 2006. Skeletal muscle dysfunction in chronic renal failure: Effects of exercise. Am J Physiol Renal Physiol 290(4):F753-F761. (Pubitemid 43724931)
2. Al-Shanti N, Saini A, Faulkner SH, Stewart CE. 2008. Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts-Potential crosstalk with IGF system. Growth Factors 26(2):61-73. (Pubitemid 351584058)
3. Al-Shanti N, Stewart CE. 2009. Ca2+/calmodulin-dependent transcriptional pathways: Potential mediators of skeletal muscle growth and development. Biol Rev Camb Philos Soc 84(4):637-652.
4. Alexander WS. 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2(6):410-416. (Pubitemid 37328748)
5. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, Paolisso G. 2003. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 284(3):E481-E487. (Pubitemid 36237535)
6. Borst SE, Lowenthal DT. 1997. Role of IGF-I in muscular atrophy of aging. Endocrine 7(1):61-63. (Pubitemid 127483088)
7. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. 2003. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 88(5): 2019-2025. (Pubitemid 36549871)
8. Carson JA, Baltgalvis KA. 2010. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38(4):168-176.
9. Cheng M, Sexl V, Sherr CJ, Roussel MF. 1998. Assembly of cyclin Ddependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95(3):1091-1096.
10. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. 1997. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272(10):6653-6662. (Pubitemid 27118151)
11. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E. 1997. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 99(4):643-650. (Pubitemid 27097665)
12. de Martino M, Galli L, Chiarelli F, Verrotti A, Rossi ME, Bindi G, Galluzzi F, Salti R, Vierucci A. 2000. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection. Clin Immunol 94(3):212-218. (Pubitemid 30141749)
13. Febbraio MA, Pedersen BK. 2002. Muscle-derived interleukin-6: Mechanisms for activation and possible biological roles. Faseb J 16(11):1335-1347. (Pubitemid 34913306)
14. Florini JR, Ewton DZ, Coolican SA. 1996. Growth hormone and the insulinlike growth factor system in myogenesis. Endocr Rev 17(5):481-517. (Pubitemid 26346639)
15. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, Rotwein PS. 1991. ''Spontaneous'' differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J Biol Chem 266(24): 15917-15923. (Pubitemid 21907745)
16. Foulstone EJ, Huser C, Crown AL, Holly JM, Stewart CE. 2004. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: Roles of IGF-I and TNFalpha. Exp Cell Res 294(1):223-235. (Pubitemid 38229793)
17. Gille H, Downward J. 1999. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 274(31):22033-22040.
18. Glass DJ. 2005. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37(10):1974-1984. (Pubitemid 41206815)
19. Goodman MN. 1994. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205(2):182-185. (Pubitemid 24130273)
20. Haddad F, Zaldivar F, Cooper DM, Adams GR. 2005. IL-6-induced skeletal muscle atrophy. J Appl Physiol 98(3):911-917. (Pubitemid 40283672)
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1-20. (Pubitemid 37046923)
22. Helge JW, Stallknecht B, Pedersen BK, Galbo H, Kiens B, Richter EA. 2003. The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J Physiol 546(Pt 1):299-305. (Pubitemid 36104989)
23. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, Jansen M, Kittur SD, Antonarakis SE, Lips CJ, Sussenbach JS. 1985. The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet 69(2):157-160. (Pubitemid 15134038)
24. Kamel HK. 2003. Sarcopenia and aging. Nutr Rev 61(5 Pt 1):157-167. (Pubitemid 37259956)
25. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. 2004. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53(4):1060-1067. (Pubitemid 38436619)
26. Krutzik PO, Irish JM, Nolan GP, Perez OD. 2004. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: Techniques and clinical applications. Clin Immunol 110(3):206-221. (Pubitemid 38402001)
27. Krutzik PO, Nolan GP. 2003. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events. Cytometry A 55(2):61-70. (Pubitemid 37522508)
28. Kuemmerle JF, Zhou H, Bowers JG. 2004. IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins. Am J Physiol Gastrointest Liver Physiol 286(3):G412-G419. (Pubitemid 38250313)
29. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. 2002. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 277(51):49831-49840. (Pubitemid 36014431)
30. Laviola L, Natalicchio A, Perrini S, Giorgino F. 2008. Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. Am J Physiol Endocrinol Metab 295(5):E991-E999.
31. Lazarus DD, Moldawer LL, Lowry SF. 1993. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res 12(4):219-223. (Pubitemid 23264833)
32. Lieskovska J, Guo D, Derman E. 2002. IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res 12(6):388-398. (Pubitemid 35390277)
33. Lieskovska J, Guo D, Derman E. 2003. Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA. Growth Horm IGF Res 13(1):26-35. (Pubitemid 36285125)
34. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402-408. (Pubitemid 34164012)
35. Manjavachi MN, Motta EM, Marotta DM, Leite DF, Calixto JB. 2010. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain 151(2):345-355.
36. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. 2003. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162(6):1135-1147. (Pubitemid 37174195)
37. Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW. 2001. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276(28):25889-25893.
38. Morley JE, Baumgartner RN. 2004. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci 59(9):M924-M929.
39. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. 2001. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27(2):195-200. (Pubitemid 32157448)
40. Pedersen BK. 2009. The diseasome of physical inactivity-And the role of myokines in muscle-Fat cross talk. J Physiol 587(Pt 23):5559-5568.
41. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Wolsk-Petersen E, Febbraio M. 2004. The metabolic role of IL-6 produced during exercise: Is IL-6 an exercise factor? Proc Nutr Soc 63(2): 263-267. (Pubitemid 38787476)
42. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. 2010. The GH/IGF1 axis and signaling pathways in the muscle and bone: Mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 205(3):201-210.
43. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. 2004. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313(4):856-862. (Pubitemid 38050071)
44. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3(11):1009-1013. (Pubitemid 34428746)
45. Rosen CJ. 2000. Growth hormone and aging. Endocrine 12(2):197-201. (Pubitemid 30408740)
46. Saini A, Al-Shanti N, Faulkner SH, Stewart CE. 2008. Pro-and anti-apoptotic roles for IGF-I in TNF-alpha-induced apoptosis: A MAP kinase mediated mechanism. Growth Factors 26(5):239-253.
47. Saini A, Al-Shanti N, Stewart CE. 2006. Waste management-Cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17(6):475-486. (Pubitemid 44793120)
48. Schubert R, Geiger H, Zielen S, Baer PC. 2009. Simultaneous detection of ERK-, p38-, and JNK-MAPK phosphorylation in human adipose-derived stem cells using the Cytometric Bead Array technology. J Immunol Methods 350(1-2):200-204.
49. Sharples AP, Al-Shanti N, Lewis MP, Stewart CE. 2011a. Reduction of myoblast differentiation following multiple population doublings in mouse C(2) C(12) cells: A model to investigate ageing? J Cell Biochem. 112(12): 3773-3785.
50. Sharples AP, Al-Shanti N, Stewart CE. 2011b. C2 and C2C12 murine skeletal myoblast models of atrophic and hypertrophic potential: Relevance to disease and ageing? J Cell Physiol 225(1):240-250.
51. Singh MA, Ding W, Manfredi TJ, Solares GS, O'Neill EF, Clements KM, Ryan ND, Kehayias JJ, Fielding RA, Evans WJ. 1999. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol 277(1 Pt 1):E135-E143. (Pubitemid 29356737)
52. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. 2003. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17(8):884-886.
53. Stewart CE, James PL, Fant ME, Rotwein P. 1996. Overexpression of insulinlike growth factor-II induces accelerated myoblast differentiation. J Cell Physiol 169(1):23-32. (Pubitemid 26342512)
54. Stewart CE, Rotwein P. 1996. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271(19):11330-11338. (Pubitemid 26155970)
55. Strassmann G, Fong M, Kenney JS, Jacob CO. 1992a. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89(5):1681-1684.
56. Strassmann G, Jacob CO, Evans R, Beall D, Fong M. 1992b. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 148(11):3674-3678.
57. Takahashi T, Fukuda K, Pan J, Kodama H, Sano M, Makino S, Kato T, Manabe T, Ogawa S. 1999. Characterization of insulin-like growth factor-1-induced activation of the JAK/STAT pathway in rat cardiomyocytes. Circ Res 85(10): 884-891. (Pubitemid 29534162)
58. Tisdale M. 2002. Cachexia in cancer patients. Nat Rev Cancer 2(11):862-871. (Pubitemid 37328904)
59. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. 2003. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88(7):3005-3010. (Pubitemid 36877463)
60. Venuti JM, Cserjesi P. 1996. Molecular embryology of skeletal myogenesis. Curr Top Dev Biol 34:169-206.
61. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. 2002. Interleukin-6-deficient mice develop matureonset obesity. Nat Med 8(1):75-79. (Pubitemid 34101732)
62. Walsmith J, Roubenoff R. 2002. Cachexia in rheumatoid arthritis. Int J Cardiol 85(1):89-99.
63. Yaffe D, Saxel O. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270(5639): 725-727. (Pubitemid 8239246)
64. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D. 2001. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50(5):1110-1118. (Pubitemid 32374542)
65. Yoshiko Y, Hirao K, Maeda N. 2002. Differentiation in C(2)C(12) myoblasts depends on the expression of endogenous IGFs and not serum depletion. Am J Physiol Cell Physiol 283(4):C1278-C1286.
66. Zhang X, Steiner MS, Rinaldy A, Lu Y. 2001. Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3. Oncogene 20(42):5982-5990. (Pubitemid 32955040)
67. Zhang XW, Qing C, Xu B. 1999. Apoptosis induction and cell cycle perturbation in human hepatoma hep G2cells by 10-hydroxycamptothecin. Anticancer Drugs 10(6):569-576. (Pubitemid 29410804)